Introduction
Non-Hodgkin's lymphoma (NHL) consists of a large group of neoplasms of the immune system and represents a heterogeneous group of diseases that share the monoclonal expansion of both B-and T lymphocytes. The majority (X90%) of NHL originates from B cells and represents a subpopulation of pre-B cells and a few mature B cells (Freedman and Nadler, 1991) . The incidence of NHL continues to rise and currently NHL ranks the fifth in cancer mortality. Combination chemotherapy is the standard treatment option for aggressive NHL (Fisher et al., 1993) , although only 40% of patients with aggressive NHL are cured and the majority of patients become refractory to such treatments. Newer biological therapies have emerged during the last years and offered alternative options to treat unresponsive malignant disease. For instance, the development of monoclonal antibodies targeted against tumor cells have been met with success. Rituximab, a chimeric anti-CD20 monoclonal antibody, targets the CD20 surface antigen expressed on the surface of both normal and malignant B cells. Rituximab is the first Food and Drug Administration (FDA) approved (1997) antitumor antibody and is used for the treatment of follicular and low-grade NHL (Reff et al., 1994; Hainsworth, 2004) . The use of rituximab has expanded in combination with chemotherapy and for other B-cell malignancies (Coiffier, 2005) .
CD20 is a tetra-membrane spanning protein (MW 33-37 kDa) and is located on chromosome 11q12-q13.1 and is expressed in multimeric forms on the cell surface. CD20 is a resident in lipid raft domains of the plasma membrane (Cragg et al., 2005) . Different mechanisms have been proposed for the in vivo effect of rituximab including complement-dependent cell cytotoxicity (CDC) (Reff et al., 1994; Golay et al., 2001) , antibody-dependent cellular cytotoxicity (ADCC) (Reff et al., 1994; Kennedy et al., 2003) and apoptosis (Shan et al., 2000) . Our laboratory reported the synergistic effect of combination treatment of rituximab and chemotherapy (see the review . There remain many unresolved questions with respect to rituximab-mediated treatment responses. For instance, why do only 50% of patients respond to rituximab even though all the tumors express CD20? What is the mechanism of synergy achieved by the combination treatment of rituximab and chemotherapy? How do patients develop resistance and become refractory to rituximab treatment? Does the hostimmune system (excluding ADCC and CDC) participate in rituximab-mediated responses? Do rituximabmediated cell signaling effects provide potential approaches for novel therapeutic interventions and identification of diagnostic/prognostic biomarkers? These and other pertinent issues will be addressed below in this review.
Rituximab-mediated cell triggering and inhibition of antiapoptotic survival signaling pathways
Re-distribution of CD20 in lipid rafts The exact function of CD20 is not completely understood. Earlier studies by Deans et al. (1993 Deans et al. ( , 1995 have demonstrated that cross-linking CD20 resulted in increases in intracellular calcium and show that CD20 is associated with the Src family tyrosine kinases, suggesting the involvement of CD20 in transmembrane signaling. Cell signaling results from the association of CD20 with raft signaling platforms (Deans et al., 1998) . Cross-linking of CD20 by antibodies induces a re-distribution of CD20 molecules to specialized microdomains at the plasma membrane, known as lipid rafts. Rituximab induces re-distribution of CD20 to lipid raft without modifying the overall context in lipid surfaces and signaling proteins. This results in decrease of total protein kinase activity (measured by levels of phosphorylated Lyn and Cbp/PAG) without changes in nonphosphorylated proteins (Semac et al., 2003) . We have also confirmed the inhibition of phospho-Lyn following the treatment of B-NHL cell lines with rituximab (Jazirehi et al., 2004a) . Bezombes et al. (2004) reported that upon rituximab treatment there was rapid and transient increase in acid sphingomyelinase activity and, concomitantly, cellular ceramide generation on raft microdomains. Deans et al. (2002) suggested that growth inhibition by rituximab may be mediated through a ceramide-triggered signaling pathway leading to induction of cell-cycle-dependent kinase inhibition such as p27 through a mitogen-activated protein kinase (MAPK)-dependent mechanism. This cell signaling can also activate the apoptotic signaling pathway. This was corroborated by Janas et al. (2005) who reported that rituximab-induced translocation of CD20 to lipid rafts is important for increased intracellular calcium levels and downstream apoptotic signaling.
Inhibition of survival and antiapoptotic signaling pathways Our earlier studies with rituximab demonstrated that treatment of chemotherapy-resistant B-NHL cell lines with rituximab sensitized the cells to chemotherapyinduced apoptosis (Demiden et al., 1997) . These findings suggested that rituximab may trigger the cells and altering the apoptotic signaling pathway. Therefore, we began examining molecularly the underlying mechanisms by which rituximab chemosensitized drug-resistant B-NHL cell lines. Our initial observations revealed that rituximab treatment preferentially inhibited the expression of the antiapoptotic gene products Bcl-2/Bcl-xL . Thus, we investigated whether rituximab inhibited signaling pathways that regulate these gene products. We have found that rituximab downmodulates the p38 MAPK, nuclear factor-kB (NF-kB), ERK 1/2 and AKT survival pathways leading to downregulation of Bcl-2/Bcl-xL and chemosensitization of drug-resistant B-NHL cell lines.
Rituximab-induced inhibition of the p38 MAPK/STAT3/ NF-kB/SP1/Bcl-2 pathway. Rituximab treatment of the diffuse large B-cell lymphoma (DLBCL) AIDSderived B-NHL cell line, 2F7, resulted in inhibition of cell proliferation and selective inhibition of Bcl-2 expression. In addition, rituximab inhibited interleukin-10 (IL-10) secretion from 2F7. We hypothesized that IL-10 may act as an autocrine/paracrine growth factor and this activates STAT3 activity via IL-10-IL-10-receptor triggering and, downstream, STAT3-induced downregulation of Bcl-2. We have found that rituximab treatment disrupts the IL-10 autocrine/paracrine loop, resulting in the inhibition of STAT3 activity and Bcl-2 expression. Further, we demonstrate that inhibition of IL-10 was under the regulation of the p38 MAPK and the transcription factor SP-1 Vega et al., 2004) . It is noteworthy that the levels of IL-10 are increased in many NHL patients and higher circulating levels of IL-10 were shown to correlate with a lower rate of survival (Blay et al., 1993) . These findings suggest a potential in vivo mechanism of rituximab-mediated effect by interfering with IL-10 and other growth factors.
Rituximab-induced inhibition of the Src/Raf 1/MEK1/2/ ERK1/2/AP-1/Bcl-xL pathway. The above studies performed with the DLBCL cell line were also performed with the FL-NHL cell lines. Treatment of Ramos and Daudi cell lines with rituximab preferentially downregulated Bcl-xL expression with minimal effect on Bcl-2 expression in Daudi as Ramos is Bcl-2 negative (Jazirehi et al., 2003) . Bcl-x expression is under the transcriptional control of both the ERK 1/2 and NF-kB signaling pathways. We first examined whether rituximab inhibits the Raf-1/AP-1 pathway and leading to downregulation of Bcl-xL expression. Both Ramos and Daudi exhibit constitutively activated ERK1/2 pathway and following treatment with rituximab there was significant inhibition of the phosphorylated state of Raf-1/MEK1/2 and ERK 1/2 and the inhibition was observed at 3-6 h after rituximab treatment. In addition, the MEK1/2 kinase activity was inhibited and thus corroborating the dephosphorylating data. Inhibition of the ERK1/2 pathway by rituximab resulted in inhibiting AP-1 DNA-binding activity and Bcl-x transcription. Several lines of evidence supported the role of rituximabinduced inhibition of the ERK1/2 pathway and Bcl-xL expression. Further studies examined potential underlying mechanisms of rituximab-induced inhibition of the ERK 1/2 pathway. The Raf kinase inhibitor protein (RKIP) has been reported as a negative regulator of the activation of the ERK 1/2 pathway (Yeung et al., 1999 (Yeung et al., , 2000 . We hypothesized that rituximab may be inducing RKIP expression leading to inhibition of the ERK 1/2 activated pathway. Indeed, the findings revealed that rituximab treatment upregulated RKIP expression and the augmentation of RKIP also resulted in its association with Raf-1 (Jazirehi et al., 2004a) . These findings revealed a novel mechanism of rituximab-mediated effect in FL-NHL cell lines and its clinical implication will be discussed below. Noteworthy, Bcl-xL expression was shown to be abundant in lymphoma and shown to participate in protecting the cells from DNA-damaging agents (Xerri et al., 1996) . Hence, our findings with rituximab-induced inhibition of Bcl-xL in FL-NHL cell lines may have bearing to rituximab-mediated clinical response in vivo.
Rituximab-induced inhibition of the NF-kB/Bcl-xL constitutively activated pathway. As mentioned above, Bcl-x expression is also regulated by the NF-kB pathway (Dixit and Mak, 2002; Ghosh and Karin, 2002) . Hence, we investigated the effect of rituximab treatment on the constitutively activated NF-kB pathway in Ramos and Daudi. We have found that rituximab decreases the phosphorylation state of NF-kB-inducing kinase IkB kinase (IKK) and IkBa and diminishes IKK kinase activity and NF-kB DNA-binding activity. This inhibition led to downregulation of Bcl-xL expression. In addition, as discussed above for RKIP-induced inhibition of the ERK 1/2 pathway, RKIP was also shown to inhibit the activity of the NF-kB pathway (Yeung et al., 2001) . Since rituximab induced RKIP expression, we have found that RKIP inhibits the activity of the NF-kB pathway through its physical association with endogenous NF-kB-inducing kinase, transforming growth factor-b-activated kinase 1 (TAK1) and IKK. These findings established that rituximab inhibits the activity of the NF-kB pathway and inhibition of this pathway is in part regulated by the induction of RKIP expression. Several lines of evidence supported the role of the NF-kB pathway in the regulation of Bcl-x expression and its inhibition by rituximab (Jazirehi et al., 2005) .
Rituximab-induced inhibition of the constitutively activated AKT/Bcl-xL pathway. Another pathway that regulates Bcl-xL expression and activity is the AKT pathway. Regulation of Bcl-xL is via its antiapoptotic function and transcription (Vivanco and Sawyers, 2002) . Treatment of Ramos and Daudi with rituximab resulted in significant inhibition of the constitutively activated AKT pathway. Rituximab inhibited the phosphorylated state of PI3K, PDK-1, AKT and Bad with no effect on unphosphorylated forms. Inhibition of phosphorylation Bad augmented the association of Bad with Bcl-xL to form complexes. In addition, inhibition of active AKT inhibits NF-kB activity. Hence, inhibition of the AKT pathway by rituximab resulted in significant inhibition of both Bcl-xL function and expression. In addition, we examined whether rituximab regulates the activity of the AKT inhibitor phosphatase, phosphatase and tensin homolog deleted on chromosome ten (PTEN), and indeed, we have found that PTEN expression was unregulated by rituximab. Hence, we demonstrate a novel mechanism of rituximab-mediated inhibition of the AKT pathway and its inhibition was, in part, regulated by the induction of PTEN expression (Suzuki and Bonavida, 2007) .
Involvement of rituximab-mediated inhibition of the constitutively activated p38 MAPK, ERK 1/2, NF-jB and AKT pathways and reversal of drug resistance We have shown above that rituximab treatment of NHL cell lines results in significant inhibition of several survival antiapoptotic pathways, all of which result in the preferential downregulation of antiapoptotic gene products such as Bcl-2 and Bcl-xL . Downregulation of Bcl-2 or Bcl-xL expression was shown to be pivotal in the reversal of chemoresistance. These findings implied that pharmacologic inhibitors of the above pathways should mimic rituximab and when used in combination with cytotoxic drugs should also reverse chemoresistance. This hypothesis was investigated with each of the four signaling pathways above that have been shown to be modified by rituximab. In studies with the DLBCL cell line 2F7, in which rituximab inhibits the p38 MAPK/ STAT3/Bcl-2 expression, we demonstrate that treatment of 2F7 with pharmacologic inhibitors of p38 MAPK (SB203580), NF-kB (Bay 11-7085) and STAT3 (piceatannol) all resulted in inhibition of Bcl-2 expression and sensitization to apoptosis by various chemotherapeutic drugs (Alas and Bonavida, 2003; Vega et al., 2004) . In addition, with the FL-NHL cell lines, Ramos and Daudi, we demonstrate that treatment by pharmacologic inhibitors of the ERK 1/2 pathway (GW-5074, PD-8098059 and UO-126) all resulted in chemosensitization. In addition, an inhibitor of Bcl-2 family members (2-MAM-A3), which inhibits their antiapoptotic function, also sensitized the tumor cells to drug-induced apoptosis (Jazirehi et al., 2004a) . Likewise, treatment with inhibitors of the NF-kB pathways (Bay 11-7085, DHMEQ and SN-50) all sensitized the drug-resistant cell lines to drug-induced apoptosis (Jazirehi et al., 2004a) . The role of the activated AKT pathway in resistance was corroborated by the use of the specific pharmacological inhibitor LY-294002 and by AKT siRNA, both of which inhibited Bcl-xL expression and sensitized the cells to drug-induced apoptosis (Suzuki and Bonavida, 2007) .
Overall, the above findings established the underlying molecular mechanisms by which rituximab sensitizes drug-resistant B-NHL cell lines to apoptosis by various subtoxic concentrations of chemotherapeutic drugs. In addition, the findings identified several new targets for both therapeutic intervention and biomarkers (see below).
Rituximab-mediated immunosensitization of B-NHL cell lines to apoptosis by Fas ligand and TRAIL
The above findings established several mechanisms by which rituximab sensitized drug-resistant B-NHL cell lines to drug-induced apoptosis via interference with several intracellular antiapoptotic survival signaling pathways. Based on these findings and our previous findings implicating the role of NF-kB activity in the regulation of resistance to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), we hypothesized that rituximab may sensitize B-NHL cell lines to both Fas ligand and TRAILinduced apoptosis. Previous findings have demonstrated that regulation of Fas expression and sensitivity to Fas ligand were under the negative influence of both activated NF-kB and the transcription factor Yin Yang 1 (YY1). Inhibition of NF-kB or YY1 resulted in sensitization to Fas ligand-induced apoptosis (Garban and Bonavida, 2001) . We have also reported that rituximab treatment of NHL cell lines inhibited the expression and activity of both NF-kB and YY1 . In addition, we have also reported that NF-kB and YY1 negatively regulate transcription of the TRAIL receptor DR5 and hence inhibition of NF-kB or YY1 sensitized the tumor cells to TRAIL-induced apoptosis ). Thus, we tested the above hypothesis and indeed we demonstrate that treatment of NHL cell lines with rituximab sensitized the cells to Fas ligand-induced apoptosis and correlated with upregulation of Fas expression. The role of YY1 in the regulation of Fas ligand-induced sensitization was corroborated by several lines of evidence. In addition, we also demonstrate that the synergy in apoptosis achieved with the combination of rituximab and Fas ligand is the result of triggering the Type II mitochondrial pathway of apoptosis (Vega et al., 2005a, b) . The findings with rituximab were mimicked by the use of pharmacologic inhibitors of the NF-kB pathway or of the direct inhibition of YY1. We have also examined the effect of rituximab on tumor cell resistance to TRAIL. Recent studies from our laboratories have established that YY1 negatively regulates DR5 transcription and expression (Baritaki et al., 2007) . Therefore, we examined the upregulation of DR5 and the sensitization of B-NHL cell lines to TRAIL-induced apoptosis as a consequence of rituximab-induced inhibition of NF-kB and YY1. Our findings revealed that treatment with rituximab upregulates surface and total DR5 expression and sensitized NHL cell lines to TRAIL-induced apoptosis (Vega, et al., in preparation) . The above findings have established a novel potential mechanism of rituximab-mediated activity in vivo. These findings establish, for the first time, the role of host-effector cells expressing Fas ligand or TRAIL in the destruction of tumor cells following their treatment with rituximab. The clinical implication of these findings will be discussed below.
Underlying mechanisms of the development of rituximab resistance
It is well recognized that treatment with rituximab alone results in 50% clinical response and it is not clear why the remaining 50% of patients do not respond. Further, a subset of responsive patients develops or acquires resistance to further treatment and the mechanism of resistance in this subset is also not clear. There have been some reports suggesting the modulation of CD20 expression and/or circulating CD20 as responsible for unresponsiveness (Haidar et al., 2003; Manshouri et al., 2003; Kennedy et al., 2004) . Based on our findings described above, we hypothesized that the development/ acquisition of rituximab resistance may have emanated from perturbations of tumor cells survival signaling pathways and failure of rituximab to alter these pathways. In effort to test this hypothesis, we have generated rituximab-resistant clones of Ramos, Daudi and 2F7 following extended culture of the cells in the presence of increasing concentrations of rituximab. Representative clones were examined for responsiveness following treatment with rituximab and were compared to responsiveness with wild-type rituximab. Examination of these clones showed reduction but no loss of CD20 expression and the clones failed to respond to CDC, cell growth inhibition and apoptosis following treatment with rituximab (even at very high concentrations of rituximab). The clones exhibited hyperactivation of the p38 MAPK, NF-kB and ERK1/2 pathways and exhibited overexpression of Bcl-2/Bcl-xL (Jazirehi et al., 2004b (Jazirehi et al., , 2006 (Jazirehi et al., , 2007 . Preliminary findings suggest that rituximab treatment of the clones failed to induce CD20 migration into the lipid rafts (Jazirehi et al., 2006) . We have also examined the effect of various pharmacologic inhibitors that were shown to sensitize wild-type cells to apoptosis by various chemotherapeutic drugs. Our findings demonstrate that these pharmacological inhibitors as well as Bortezomib, a proteasome inhibitor, sensitize the resistance clones to various cytotoxic drugs (Jazirehi et al., 2004b (Jazirehi et al., , 2006 (Jazirehi et al., , 2007 . These findings suggest that rituximab resistance can be circumvented by the use of combination treatment of pharmacological inhibitors/proteasome inhibitor with subtoxic 
